tetano
Editor, Senior Moderator
Cell Rep Med
. 2022 Jan 24;3(2):100529.
doi: 10.1016/j.xcrm.2022.100529. eCollection 2022 Feb 15.
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
Venkata-Viswanadh Edara[SUP] 1 2 3 [/SUP], Kelly E Manning[SUP] 1 2 3 [/SUP], Madison Ellis[SUP] 1 2 3 [/SUP], Lilin Lai[SUP] 1 2 3 [/SUP], Kathryn M Moore[SUP] 1 2 3 [/SUP], Stephanie L Foster[SUP] 1 2 3 [/SUP], Katharine Floyd[SUP] 1 2 3 [/SUP], Meredith E Davis-Gardner[SUP] 1 2 3 [/SUP], Grace Mantus[SUP] 1 2 4 [/SUP], Lindsay E Nyhoff[SUP] 1 2 4 [/SUP], Sarah Bechnak[SUP] 4 [/SUP], Ghina Alaaeddine[SUP] 4 [/SUP], Amal Naji[SUP] 4 [/SUP], Hady Samaha[SUP] 4 [/SUP], Matthew Lee[SUP] 4 [/SUP], Laurel Bristow[SUP] 4 [/SUP], Matthew Gagne[SUP] 5 [/SUP], Jesmine Roberts-Torres[SUP] 5 [/SUP], Amy R Henry[SUP] 5 [/SUP], Sucheta Godbole[SUP] 5 [/SUP], Arash Grakoui[SUP] 2 6 4 3 [/SUP], Marybeth Saxton[SUP] 4 [/SUP], Anne Piantadosi[SUP] 4 7 [/SUP], Jesse J Waggoner[SUP] 4 [/SUP], Daniel C Douek[SUP] 5 [/SUP], Nadine Rouphael[SUP] 4 8 [/SUP], Jens Wrammert[SUP] 1 2 [/SUP], Mehul S Suthar[SUP] 1 2 6 3 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant emerged in November 2021 and consists of several mutations within the spike. We use serum from mRNA-vaccinated individuals to measure neutralization activity against omicron in a live-virus assay. At 2-4 weeks after a primary series of vaccinations, we observe a 30-fold reduction in neutralizing activity against omicron. Six months after the initial two-vaccine doses, sera from naive vaccinated subjects show no neutralizing activity against omicron. In contrast, COVID-19-recovered individuals 6 months after receiving the primary series of vaccinations show a 22-fold reduction, with the majority of the subjects retaining neutralizing antibody responses. In naive individuals following a booster shot (third dose), we observe a 14-fold reduction in neutralizing activity against omicron, and over 90% of subjects show neutralizing activity. These findings show that a third dose is required to provide robust neutralizing antibody responses against the omicron variant.
Keywords: B.1.1.529; Omicron; Omicron variant; SARS-CoV-2; antibody; booster dose; live-virus; mRNA vaccines; neutralization assay; vaccine induced immunity.
. 2022 Jan 24;3(2):100529.
doi: 10.1016/j.xcrm.2022.100529. eCollection 2022 Feb 15.
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
Venkata-Viswanadh Edara[SUP] 1 2 3 [/SUP], Kelly E Manning[SUP] 1 2 3 [/SUP], Madison Ellis[SUP] 1 2 3 [/SUP], Lilin Lai[SUP] 1 2 3 [/SUP], Kathryn M Moore[SUP] 1 2 3 [/SUP], Stephanie L Foster[SUP] 1 2 3 [/SUP], Katharine Floyd[SUP] 1 2 3 [/SUP], Meredith E Davis-Gardner[SUP] 1 2 3 [/SUP], Grace Mantus[SUP] 1 2 4 [/SUP], Lindsay E Nyhoff[SUP] 1 2 4 [/SUP], Sarah Bechnak[SUP] 4 [/SUP], Ghina Alaaeddine[SUP] 4 [/SUP], Amal Naji[SUP] 4 [/SUP], Hady Samaha[SUP] 4 [/SUP], Matthew Lee[SUP] 4 [/SUP], Laurel Bristow[SUP] 4 [/SUP], Matthew Gagne[SUP] 5 [/SUP], Jesmine Roberts-Torres[SUP] 5 [/SUP], Amy R Henry[SUP] 5 [/SUP], Sucheta Godbole[SUP] 5 [/SUP], Arash Grakoui[SUP] 2 6 4 3 [/SUP], Marybeth Saxton[SUP] 4 [/SUP], Anne Piantadosi[SUP] 4 7 [/SUP], Jesse J Waggoner[SUP] 4 [/SUP], Daniel C Douek[SUP] 5 [/SUP], Nadine Rouphael[SUP] 4 8 [/SUP], Jens Wrammert[SUP] 1 2 [/SUP], Mehul S Suthar[SUP] 1 2 6 3 [/SUP]
Affiliations
- PMID: 35233550
- PMCID: PMC8784612
- DOI: 10.1016/j.xcrm.2022.100529
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant emerged in November 2021 and consists of several mutations within the spike. We use serum from mRNA-vaccinated individuals to measure neutralization activity against omicron in a live-virus assay. At 2-4 weeks after a primary series of vaccinations, we observe a 30-fold reduction in neutralizing activity against omicron. Six months after the initial two-vaccine doses, sera from naive vaccinated subjects show no neutralizing activity against omicron. In contrast, COVID-19-recovered individuals 6 months after receiving the primary series of vaccinations show a 22-fold reduction, with the majority of the subjects retaining neutralizing antibody responses. In naive individuals following a booster shot (third dose), we observe a 14-fold reduction in neutralizing activity against omicron, and over 90% of subjects show neutralizing activity. These findings show that a third dose is required to provide robust neutralizing antibody responses against the omicron variant.
Keywords: B.1.1.529; Omicron; Omicron variant; SARS-CoV-2; antibody; booster dose; live-virus; mRNA vaccines; neutralization assay; vaccine induced immunity.